Personal and Social Performance Scale

Morosini, Pier Luigi; Magliano, Lorenza; Brambilla, L; Ugolini, S.; Pioli, Rosaria

doi:10.1037/t38751-000

Cited by 34 publications

(40 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…), a long-acting atypical injectable antipsychotic, significantly improved the PANSS total score compared with placebo, as well as CGI-S, PANSS Marder factor scores, and responder rates when administered once monthly, without oral supplementation, into the gluteal muscle in patients with symptomatic schizophrenia. The PSP scale, a validated scale that assesses personal and social functioning (Nasrallah et al, 2008;Morosini et al, 2000;Patrick et al, 2009) did not show a significant treatment difference, perhaps due to the high placebo response observed in this study.…”

Section: Discussionmentioning

confidence: 79%

“…The primary efficacy variable was the change from baseline to end point (last observation carried forward (LOCF) approach: day 92 or the last postbaseline assessment in the double-blind period) in PANSS total score. Secondary efficacy variables were changes from baseline to end point in Clinical Global Impression-Severity (CGI-S) and Personal and Social Performance (PSP) scales (Morosini et al, 2000). Other efficacy variables included PANSS subscales, PANSS Marder factor scores, and treatment responder rate (defined as patients with a X30% decrease from baseline in PANSS total score at end point).…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

A Controlled, Evidence-Based Trial of Paliperidone Palmitate, A Long-Acting Injectable Antipsychotic, in Schizophrenia

Nasrallah

Gopal

Gassmann-Mayer

et al. 2010

Neuropsychopharmacol

135

View full text Add to dashboard Cite

Paliperidone palmitate is a long-acting injectable antipsychotic agent. This 13-week, multicenter, randomized (1 : 1 : 1 : 1), double-blind, parallel-group study evaluated the efficacy, safety, and tolerability of fixed 25, 50, and 100 milligram equivalent (mg equiv.) doses of paliperidone palmitate vs placebo administered as gluteal injections on days 1 and 8, then every 4 weeks (days 36 and 64) in 518 adult patients with schizophrenia. The intent-to-treat analysis set (N ¼ 514) was 67% men and 67% White, with a mean age of 41 years. All paliperidone palmitate dose groups showed significant improvement vs placebo in the Positive and Negative Syndrome Scale (PANSS) total score (primary efficacy measure; 25 and 50 mg equiv., p ¼ 0.02; 100 mg equiv., po0.001), as well as Clinical Global Impression Severity scores (pp0.006) and PANSS negative and positive symptom Marder factor scores (pp0.04). The Personal and Social Performance scale showed no significant difference between treatment groups. The overall incidence of treatment-emergent adverse events was similar between groups. Parkinsonism, the most frequently reported extrapyramidal symptom, was reported at similar rates for placebo (5%) and paliperidone palmitate (5-6% across doses). The mean body mass index and mean weight showed relatively small dose-related increases during paliperidone palmitate treatment. Investigator-evaluated injection-site pain, swelling, redness, and induration were similar across treatment groups; scores for patient-evaluated injection-site pain (visual analog scale) were similar across groups and diminished with time. All doses of once-monthly paliperidone palmitate were efficacious and generally tolerated, both locally and systemically. Paliperidone palmitate offers the potential to improve outcomes in adults with symptomatic schizophrenia.

show abstract

Section: Discussionmentioning

confidence: 79%

Section: Discussionmentioning

confidence: 99%

A Controlled, Evidence-Based Trial of Paliperidone Palmitate, A Long-Acting Injectable Antipsychotic, in Schizophrenia

Nasrallah

Gopal

Gassmann-Mayer

et al. 2010

Neuropsychopharmacol

135

View full text Add to dashboard Cite

show abstract

“…RAF is a clinical tool contained in the handbook VADO ( Valutazione delle Abilità e Definizione degli Obiettivi –in English: Skills Assessment and Definition of Goals ), a short manual for the planning and evaluation of rehabilitative interventions22 widely used in psychiatric facilities 23. The score of each domain ranges on a 7-point scale, from 9= excellent functioning to 3= extremely severe impairment .…”

Section: Methodsmentioning

confidence: 99%

Short-Term Psychiatric Rehabilitation in Major Depressive and Bipolar Disorders: Neuropsychological-Psychosocial Outcomes

Perna

Daccò²,

Sacco³

et al. 2017

Psychiatry Investig

View full text Add to dashboard Cite

ObjectiveOur pilot study aims to investigate the efficacy of a Short-Term (4 weeks) Psychiatric Rehabilitation Program (S-T PsyRP), without specific cognitive remediation trainings, on the neuropsychological performance and psychosocial functioning of inpatients with Major Depressive Disorder (MDD) or Bipolar Disorder (BD). Published studies with similar aims are lacking.MethodsFifty-three inpatients with MDD and 27 with BD (type I/II) were included. The S-T PsyRP was usually performed as clinical practice at Villa San Benedetto Menni Hospital and included a variety of activities aimed at promoting personal autonomies, interpersonal/social skills, and self-care. At the beginning and the end of the hospitalization we evaluated: neuropsychological performance (cognitive tests on verbal/visual working memory, attention, visual-constructive ability, language fluency, and comprehension); psychosocial functioning by the Rehabilitation Areas Form (RAF, handbook VADO); illness severity by the Brief Psychiatric Rating Scale (BPRS). Repeated-measure ANOVA and Pearson's linear correlation were used.ResultsWe found significant improvement (p<0.01) in all the neuropsychological tests except for one, in 4 out of 6 RAF psychosocial areas (“involvement in ward activities”, “autonomies”, “self-care”, and “self-management of health”) and in clinical symptoms severity. No associations were found between the amelioration of clinical symptoms and neuropsychological or psychosocial improvement.ConclusionA S-T PsyRP without specific cognitive remediation trainings may improve several cognitive/functional domains in MDD or BD inpatients, probably by offering opportunities to engage in demanding problem-solving conditions and cognitively stimulating activities.

show abstract

“…The Personal and Social Performance scale (PSP) was used to assess social and occupational functioning over the past month (Morosini, Magliano, Brambilla, Ugolini, & Pioli, 2000). This is an observer-rated 100-point single-item rating scale.…”

Section: Functioningmentioning

confidence: 99%

Exploring functional impairment in young people at ultra‐high risk for psychosis: A qualitative study

Cotter

Bucci

Drake

et al. 2018

Early Intervention Psych

View full text Add to dashboard Cite

show abstract

Personal and Social Performance Scale

Cited by 34 publications

References 6 publications

A Controlled, Evidence-Based Trial of Paliperidone Palmitate, A Long-Acting Injectable Antipsychotic, in Schizophrenia

A Controlled, Evidence-Based Trial of Paliperidone Palmitate, A Long-Acting Injectable Antipsychotic, in Schizophrenia

Short-Term Psychiatric Rehabilitation in Major Depressive and Bipolar Disorders: Neuropsychological-Psychosocial Outcomes

Exploring functional impairment in young people at ultra‐high risk for psychosis: A qualitative study

Contact Info

Product

Resources

About